Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, sofosbuvir (Sovaldi ®) cannot be endorsed within NHS Wales for use in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in paediatric patients aged 3 to <12 years. |
||
|
||
Medicine details |
||
| Medicine name | sofosbuvir (Sovaldi®) | |
| Formulation | multiple | |
| Reference number | 4589 | |
| Indication | In combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in paediatric patients aged 3 to < 12 years |
|
| Company | Gilead Sciences Ltd | |
| BNF chapter | Infections | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 13/11/2020 | |